Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers

Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers

Immunotherapy has transformed the management of patients with advanced melanoma, with five-year overall survival rates reaching 52% for combination immunotherapies blocking the cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) and programmed cell death-1 (PD1) immune axes. Yet, our understanding o...

Full description

Bibliographic Details
Main Authors: Elena Shklovskaya, Bernadette Pedersen, Ashleigh Stewart, Jack O. G. Simpson, Zizhen Ming, Mal Irvine, Richard A. Scolyer, Georgina V. Long, Helen Rizos
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cancers
Subjects:
immune checkpoint blockade
melanoma
mouse models
antigen presentation
major histocompatibility (MHC) class I
interferon
Online Access:https://www.mdpi.com/2072-6694/14/19/4830

Internet

https://www.mdpi.com/2072-6694/14/19/4830

Similar Items